IanWinchesterFlinnMD

Oncology • Nashville, TN

Hematologic Oncology

Physician

Join to view full profile

Dr. Flinn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Flinn's full profile

Already have an account?

Office
250 25th Ave N
Ste 412
Nashville, TN 37203
Phone+1 615-986-7600

Fax+1 615-986-7601
Is this information wrong?

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1993 - 1996
University of Michigan Health SystemResidency, Internal Medicine, 1990 - 1993
Johns Hopkins University School of MedicineClass of 1990

Certifications & Licensure

TN State Medical License 2006 - 2025
AL State Medical License 2020 - 2020
MD State Medical License 1993 - 2006
MI State Medical License 1992 - 1996
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2008-2014
Nashville Lifestyles Magazine Castle Connolly, 2008, 2011, 2013-2014
America's Top Doctors for Cancer Castle Connolly, 2007-2013

Clinical Trials

Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2000 Mar 09
Completed
Phase 3
Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2001 Jul 05
Completed
Phase 2
Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma Start of enrollment: 2003 Mar 01
Completed
Phase 3
Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients Start of enrollment: 2004 Mar 01
Unknown status
Phase 2
Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2005 Jul 01
Terminated
Phase 2
Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma Start of enrollment: 2006 Jul 01
Completed
Phase 1
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2008 Jan 01
Completed
Phase 1, Phase 2
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma Start of enrollment: 2008 Jun 01
Completed
Phase 1, Phase 2
Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma Start of enrollment: 2010 Mar 01
Completed
Phase 2
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2010 Jul 01
Completed
Phase 2
Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia Start of enrollment: 2010 Sep 01
Completed
Phase 1
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Start of enrollment: 2012 Jan 01
Completed
Phase 1
A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies Start of enrollment: 2012 Oct 01
Completed
Phase 1
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
Terminated
Phase 3
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
Terminated
Phase 2
Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma Start of enrollment: 2013 Dec 05
Completed
Phase 1
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies Start of enrollment: 2013 May 01
Completed
Phase 1
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Start of enrollment: 2013 Sep 05
Completed
Phase 1
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Feb 05
Terminated
Phase 3
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL Start of enrollment: 2013 Aug 30
Completed
Phase 1, Phase 2
Study of the Glutaminase Inhibitor CB-839 in Leukemia Start of enrollment: 2014 Mar 01
Completed
Phase 1
Selinexor (KPT-330) in Older Patients With Relapsed AML Start of enrollment: 2014 Mar 01
Completed
Phase 2
Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML Start of enrollment: 2014 Oct 01
Withdrawn
Phase 1
AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2016 Jun 01
Withdrawn
Phase 1
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) Start of enrollment: 2018 Jun 19
Completed
Phase 1
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma Start of enrollment: 2018 Nov 28
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Start of enrollment: 2021 Nov 12
Recruiting
Phase 2
Roles: Contact
Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma Start of enrollment: 2023 Jan 02
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.
Lihua E Budde, Sarit Assouline, Laurie H Sehn, Stephen J Schuster, Sung-Soo Yoon, Dok Hyun Yoon, Matthew J Matasar, Francesc Bosch, Won Seog Kim, Loretta J Nastoupil, ...> ;Journal of Clinical Oncology. 2024 Mar 28
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Xu, L., Shadman, M., Flinn, I., Levy, M., Porter, R., Burke, J., Zafar, S., Cultrera, J., Misleh, J., Kingsley, E., Yimer, H., Freeman, B., Chaudhry, A., Tumula, P., G...> ;Haematologica. 2024 Jan 25
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial.
Matthew Matasar, Nancy L Bartlett, Mazyar Shadman, Lihua E Budde, Ian Flinn, Gareth P Gregory, Won Seog Kim, Georg Hess, Dima El-Sharkawi, Catherine S Diefenbach, Huan...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Apr 1
2 citations
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma.
Jennifer A Woyach, Ian W Flinn, Seema A Bhat, Ronald E Savage, Feng Chai, Sudharshan Eathiraj, Sean D Reiff, Elizabeth M Muhowski, Lindsey Granlund, Lyndsey Szuszkiewi...> ;Cancer Discovery. 2024 Jan 12
10 citations
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nancy L Bartlett, Sarit Assouline, Pratyush Giri, Stephen J Schuster, Chan Y Cheah, Matthew Matasar, Gareth P Gregory, Dok Hyun Yoon, Mazyar Shadman, Keith Fay, Sung-S...> ;Blood Advances. 2023 Sep 12
5 citations
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.
Barr, P. M., Barr, P. M., John N Allan, Ian W Flinn, Tanya Siddiqi, Paolo Ghia, Constantine S Tam, Thomas J Kipps, Paul M Barr, Anna Elinder Camburn, Alessandra Tedesc...> ;Clinical Cancer Research. 2023 Jul 14
1 citations
Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment.
Mark Roschewski, Manish R Patel, Patrick M Reagan, Nakhle S Saba, Graham P Collins, Hendrik-Tobias Arkenau, Sven de Vos, Barrett Nuttall, Melih Acar, Kathleen Burke, R...> ;Clinical Cancer Research. 2023 Sep 1
11 citations
A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development.
Michael J Dickinson, Pere Barba, Ulrich Jäger, Nirav N Shah, Didier Blaise, Javier Briones, Leyla Shune, Nicolas Boissel, Attilio Bondanza, Luisa Mariconti, Anne-Laure...> ;Cancer Discovery. 2023 Sep 6
5 citations
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
Michael L Wang, Wojciech Jurczak, Pier Luigi Zinzani, Toby A Eyre, Chan Y Cheah, Chaitra S Ujjani, Youngil Koh, Koji Izutsu, James N Gerson, Ian Flinn, Benoit Tessouli...> ;Journal of Clinical Oncology. 2023 Aug 20
47 citations
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Sattva S Neelapu, Caron A Jacobson, Armin Ghobadi, David B Miklos, Lazaros J Lekakis, Olalekan O Oluwole, Yi Lin, Ira Braunschweig, Brian T Hill, John M Timmerman, Abh...> ;Blood. 2023 May 11
Is there still a role for PI3K inhibitors in CLL?
Ian W Flinn> ;Clinical Advances in Hematology & Oncology. 2023 Apr 1
19 citations
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single...
Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan F Porter, John M Burke, Syed F Zafar, Jamal Misleh, Edwin C Kingsley, Habte A Yimer, Benjamin Freeman, Subramanya S Rao...> ;The Lancet. Haematology. 2023 Jan 1
42 citations
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumabchlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMI...
Carol Moreno, Richard Greil, Fatih Demirkan, Alessandra Tedeschi, Bertrand Anz, Loree Larratt, Martin Simkovic, Jan Novak, Vladimir Strugov, Devinder Gill, John G Grib...> ;Haematologica. 2022 Sep 1
7 citations
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymph...
Franck Morschhauser, Loretta Nastoupil, Pierre Feugier, Jean-Marc Schiano de Colella, Hervé Tilly, Maria Lia Palomba, Emmanuel Bachy, Christophe Fruchart, Edward N Lib...> ;Journal of Clinical Oncology. 2022 Oct 1
60 citations
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 t...
Constantine S Tam, Jennifer R Brown, Brad S Kahl, Paolo Ghia, Krzysztof Giannopoulos, Wojciech Jurczak, Martin Šimkovič, Mazyar Shadman, Anders Österborg, Luca Laurent...> ;The Lancet. Oncology. 2022 Aug 1
8 citations
A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma.
Kristie A Blum, Jeffrey G Supko, Michael B Maris, Ian W Flinn, Andre Goy, Anas Younes, Suresh Bobba, Adrian M Senderowicz, Sergey Efuni, Ronda Rippley, Gozde Colak, Pa...> ;Cancer Research Communications. 2022 Aug 1
52 citations
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
Michael L Wang, Wojciech Jurczak, Mats Jerkeman, Judith Trotman, Pier L Zinzani, David Belada, Carola Boccomini, Ian W Flinn, Pratyush Giri, Andre Goy, Paul A Hamlin, ...> ;The New England Journal of Medicine. 2022 Jun 30
70 citations
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
Michael Wang, Javier Munoz, Andre Goy, Frederick L Locke, Caron A Jacobson, Brian T Hill, John M Timmerman, Houston Holmes, Samantha Jaglowski, Ian W Flinn, Peter A Mc...> ;Journal of Clinical Oncology. 2023 Jan 20
70 citations
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatme...
Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M Pagel, Ian W Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Maria Fog...> ;Leukemia. 2022 Apr 1
422 citations
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Frederick L Locke, David B Miklos, Caron A Jacobson, Miguel-Angel Perales, Marie-José Kersten, Olalekan O Oluwole, Armin Ghobadi, Aaron P Rapoport, Joseph McGuirk, Joh...> ;The New England Journal of Medicine. 2022 Feb 17
174 citations
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
Michael R Bishop, Michael Dickinson, Duncan Purtill, Pere Barba, Armando Santoro, Nada Hamad, Koji Kato, Anna Sureda, Richard Greil, Catherine Thieblemont, Franck Mors...> ;The New England Journal of Medicine. 2022 Feb 17
121 citations
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.
Lihua E Budde, Sarit Assouline, Laurie H Sehn, Stephen J Schuster, Sung-Soo Yoon, Dok Hyun Yoon, Matthew J Matasar, Francesc Bosch, Won Seog Kim, Loretta J Nastoupil, ...> ;Journal of Clinical Oncology. 2022 Feb 10
The impact of early versus late tocilizumab administration in patients with cytokine release syndrome secondary to immune effector cell therapy
Rachel Peaytt, Laura Beth Parsons, Darby Siler, Rachel Matthews, Belinda K. Li, David Bell, Carlos Bachier, Jeremy Pantin, Jesus G. Berdeja, Ian W. Flinn, William B. D...> ;Journal of Oncology Pharmacy Practice. 2021 Nov 24
1 citations
Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study.
Tycel Phillips, Mark Brunvand, Andy I. Chen, James Essell, Annalisa Chiappella, Catherine Diefenbach, Ji Cheng, David Ramies, Jamie Hirata, Franck Morschhauser, Ian W....> ;American Journal of Hematology. 2021 Nov 3
82 citations
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized...
William G. Wierda, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Stephen Opat, Alessandra Tedeschi, Xavier C. Badoux, Bryone J. Kuss, Sharon Jackson, Carol Moreno, Ry...> ;Journal of Clinical Oncology. 2021 Oct 7
Join now to see all

Journal Articles

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Mark P Chao, Sonali M Smith, Ranjana Advani, Ian Flinn, Ravindra Majeti, Nancy L Bartlett, Leslie Popplewell, Justin Kline, Nilanjan Ghosh, Ann LaCasce, The New England Journal of Medicine
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
Ian W Flinn, Nancy L Bartlett, The New England Journal of Medicine
PI3K Inhibitors and the Search for the Holy Grail
Ian Flinn, MD, Blood
The Phase 3 DUO Trial: Duvelisib Versus Ofatumumab in Relapsed and Refractory CLL/SLL
Matthew S Davids, Ian W Flinn, Craig A Portell, Nicole Lamanna, Scott Lunin, Amanda F Cashen, Blood
Join now to see all

Abstracts/Posters

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus L...
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Analysis of an Online Treatment Decision Tool Reveals Variances in Practice between Experts and Oncology Healthcare Providers for Newly Diagnosed Follicular Lymphoma
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inh...
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of t...
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase...
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post_Axi-Cel
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies
Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Effect of dose modifications on response to duvelisib in patients with relapsed/refractory (R/R) CLL/SLL in the DUO trial.
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance for Clinical Management
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Avadomide (CC-), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Efficacy and Safety of Venetoclax (Ven) + Rituximab (R) or Ven + Bendamustine (B) + R Randomized Versus B + R in Patients (pts) with Relapsed/Refractory (R/R) Follicul...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
PI3 Kinase Inhibitors: Community Perspectives for Optimizing Therapy
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Press Mentions

SGN35-027: Brentuximab Vedotin with Nivolumab, Doxorubicin, and Dacarbazine in HLFebruary 24th, 2022
Tisagenlecleucel Promising in R/R Follicular LymphomaJanuary 11th, 2022
Will Bispecific Antibodies Challenge CAR T-cell Therapy in Follicular Lymphoma?December 21st, 2021
Join now to see all